BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Alopecia areata clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for alopecia areata: 83 (54 sponsors; 20 newly posted in the last 180 days, 6 stopped in the last 180 days; 11 new-entrant sponsors). Momentum score 24.1, rank 15 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 6, Phase 2 19, Phase 3 26, Phase 4 0, N/A 31.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Pfizer PFE | 8 | P3 4, NA 4 | 2 | 2 |
| AbbVie ABBV | 4 | NA 1, P3 3 | 1 | 0 |
| Veradermics, Inc. MANE | 4 | P3 3, P2 1 | 0 | 1 |
| Applied Biology, Inc. | 3 | P3 2, P2 1 | 0 | 2 |
| EMS | 2 | P3 2 | 0 | 1 |
| Eurofarma Laboratorios S.A. | 2 | P3 2 | 0 | 0 |
| Sun Pharmaceutical Industries, Inc. | 2 | P3 2 | 0 | 1 |
| Eli Lilly and Company LLY | 2 | P2 1, P3 1 | 0 | 0 |
| Industrial Farmacéutica Cantabria, S.A. | 2 | P3 1, NA 1 | 0 | 0 |
| Pelage Pharmaceuticals, Inc. new entrant | 2 | P3 1, P2 1 | 2 | 0 |
| Apsen Farmaceutica S.A. | 1 | P3 1 | 0 | 0 |
| Chong Kun Dang Pharmaceutical | 1 | P3 1 | 0 | 0 |
| Sun Pharma Japan Limited new entrant | 1 | P3 1 | 1 | 0 |
| Suzhou Kintor Pharmaceutical Inc, | 1 | P3 1 | 0 | 0 |
| Triple Hair Inc | 1 | P3 1 | 0 | 0 |
| Restore Biologics Holdings, Inc. dba Xtressé | 6 | P2 1, NA 5 | 2 | 3 |
| Jiangsu vcare pharmaceutical technology co., LTD new entrant | 2 | P1 1, P2 1 | 2 | 0 |
| Olistic Research Labs S.L. new entrant | 2 | NA 2 | 2 | 2 |
| Target PharmaSolutions, Inc. TGT | 2 | NA 2 | 1 | 0 |
| Absci Pty Ltd. ABSI | 1 | P2 1 | 0 | 0 |
| Acorn Biolabs Inc. | 1 | NA 1 | 0 | 0 |
| Activ'inside new entrant | 1 | NA 1 | 1 | 1 |
| Aldena Therapeutics | 1 | P2 1 | 0 | 0 |
| Almirall, S.A. | 1 | P2 1 | 0 | 0 |
| Bionos Biotech S.L. | 1 | NA 1 | 0 | 0 |
New-entrant sponsors: Pelage Pharmaceuticals, Inc., Sun Pharma Japan Limited, Jiangsu vcare pharmaceutical technology co., LTD, Olistic Research Labs S.L., Activ'inside.
Recently stopped trials
- NCT06501924 Applied Biology, Inc. - withdrawn: Sponsor change of formulation Clinical Study of DA-002 and DA-005 as a Treatment for Hair Loss
- NCT07402330 Applied Biology, Inc. - withdrawn: Change of protocol moved to new study Pharmacokinetic Study of DA-020
- NCT07033845 Applied Biology, Inc. - withdrawn: Combined into another study Pharmacokinetic Study of Topical Phenylephrine
- NCT06560385 GenieBiome Limited - terminated: No enough subjects within the recruitment period Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula
- NCT06444451 Sanofi - terminated: Sponsor decision; the decision is not related to any safety concern A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Parti
- NCT06932393 Guangzhou Bio-gene Technology Co., Ltd - terminated: Per updated regulatory requirements, the site is ineligible to proceed. The clinical institution office has terminated the project. Exosomes for Hairloss Treatment
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12 est. | P3 | Veradermics, Inc. MANE | NCT06972264 Safety and Efficacy of VDPHL01 in Males With AGA | Androgenetic Alopecia; AGA; Male Pattern Baldness | active not recruiting | 480 |
| 2026-12-02 est. | P3 | Pfizer PFE | NCT07029711 A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata | Severe Alopecia Areata | active not recruiting | 208 |
| 2027-02-05 est. | P1/P2 | Applied Biology, Inc. | NCT07397325 Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | Chemotherapy Induced Alopecia; Chemotherapy Side Effects | recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P1/P2 | Aldena Therapeutics | NCT06826196 A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata | Alopecia Areata (AA) | active not recruiting | 9 |
| 2026-10-31 est. | P2 | NEXTGEN Bioscience | NCT06104839 Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata | Alopecia Areata | recruiting | 73 |
| 2026-10 est. | P3 | Industrial Farmacéutica Cantabria, S.A. | NCT05888922 Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia | Androgenetic Alopecia; Female Pattern Baldness | active not recruiting | 520 |
| 2026-09 est. | P1/P2 | Moogene Medi Co., Ltd | NCT07490327 Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia | Androgenetic Alopecia | not yet recruiting | 30 |
| 2026-08 est. | P2 | Veradermics, Inc. MANE | NCT06527365 Safety and Efficacy of VDPHL01 in Males and Females With AGA | Androgenetic Alopecia; AGA; Male Pattern Baldness | active not recruiting | 70 |
| 2026-06-30 est. | P1/P2 | PT. Prodia Stem Cell Indonesia | NCT07429253 Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients | Androgenetic Alopecia | recruiting | 40 |
| 2026-06-06 | P3 | Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. | NCT07080931 Efficacy and Safety of 5% Minoxidil Foam in Female Androgenetic Alopecia | Androgenetic Alopecia | completed | 296 |
| 2026-06 est. | P2 | Q32 Bio Inc. QTTB | NCT06018428 A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) | Alopecia Areata | active not recruiting | 75 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "alopecia areata"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.